HomeCompareNVRVF vs ABBV

NVRVF vs ABBV: Dividend Comparison 2026

NVRVF yields 2000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NVRVF wins by $9939315158.43M in total portfolio value
10 years
NVRVF
NVRVF
● Live price
2000.00%
Share price
$0.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$9939315158.53M
Annual income
$9,049,252,674,478,578.00
Full NVRVF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — NVRVF vs ABBV

📍 NVRVF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNVRVFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NVRVF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NVRVF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NVRVF
Annual income on $10K today (after 15% tax)
$170,000.00/yr
After 10yr DRIP, annual income (after tax)
$7,691,864,773,306,791.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, NVRVF beats the other by $7,691,864,773,285,735.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NVRVF + ABBV for your $10,000?

NVRVF: 50%ABBV: 50%
100% ABBV50/50100% NVRVF
Portfolio after 10yr
$4969657579.32M
Annual income
$4,524,626,337,251,675.00/yr
Blended yield
91.05%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

NVRVF
No analyst data
Altman Z
-1.3
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NVRVF buys
0
ABBV buys
0
No recent congressional trades found for NVRVF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNVRVFABBV
Forward yield2000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$9939315158.53M$102.3K
Annual income after 10y$9,049,252,674,478,578.00$24,771.77
Total dividends collected$9876141646.27M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NVRVF vs ABBV ($10,000, DRIP)

YearNVRVF PortfolioNVRVF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$210,700$200,000.00$11,550$430.00+$199.2KNVRVF
2$4,163,767$3,938,317.76$13,472$627.96+$4.15MNVRVF
3$77,191,133$72,735,902.82$15,906$926.08+$77.18MNVRVF
4$1,342,813,676$1,260,219,163.76$19,071$1,382.55+$1342.79MNVRVF
5$21,925,333,121$20,488,522,486.99$23,302$2,095.81+$21925.31MNVRVF
6$336,109,296,351$312,649,189,912.21$29,150$3,237.93+$336109.27MNVRVF
7$4,838,913,266,619$4,479,276,319,522.88$37,536$5,121.41+$4838913.23MNVRVF
8$65,446,276,951,058$60,268,639,755,775.59$50,079$8,338.38+$65446276.90MNVRVF
9$831,834,097,245,644$761,806,580,908,011.90$69,753$14,065.80+$831834097.18MNVRVF
10$9,939,315,158,531,418$9,049,252,674,478,578.00$102,337$24,771.77+$9939315158.43MNVRVF

NVRVF vs ABBV: Complete Analysis 2026

NVRVFStock

Novra Technologies Inc., together with its subsidiaries, provides hardware, software, and services for the distribution of satellite data in Canada, North America, Central America, South America, Europe, the Middle East, Africa, East Asia, South Asia, Southeast Asia, and Oceania. The company offers video distribution products and systems for the provision of end-to-end solutions to traditional and non-traditional video networks; infrastructure solutions for broadcast radio networks, including uplink and receive site equipment, as well as network management, encryption, and targeted regionalization/ad insertion options; and data distribution for hardware infrastructure, as well as content distribution network software solution. It also provides digital cinema network infrastructure and services; appliances for cinemas; decoders for live events; alternative content in 2D and 3D; digital cinema distribution software solutions; and DVB and ATSC compliant receivers for the broadband communications network market. The company was founded in 2000 and is headquartered in Winnipeg, Canada.

Full NVRVF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this NVRVF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NVRVF vs SCHDNVRVF vs JEPINVRVF vs ONVRVF vs KONVRVF vs MAINNVRVF vs JNJNVRVF vs MRKNVRVF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.